摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-nitro-2-pyridyl)-2-pyridylamine | 71008-51-0

中文名称
——
中文别名
——
英文名称
(3-nitro-2-pyridyl)-2-pyridylamine
英文别名
2-(2-pyridylamino)-3-nitropyridine;3-Nitrobis(2-pyridyl)amine;(3-nitro-pyridin-2-yl)-pyridin-2-yl-amine;2-(pyridin-2-ylamino)-3-nitro-pyridine;2-(2-pyridylamino)-3-nitro-pyridine;3-Nitro-N-(pyridin-2-yl)pyridin-2-amine;3-nitro-N-pyridin-2-ylpyridin-2-amine
(3-nitro-2-pyridyl)-2-pyridylamine化学式
CAS
71008-51-0
化学式
C10H8N4O2
mdl
——
分子量
216.199
InChiKey
VXZKJRZDVQZVJS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    83.6
  • 氢给体数:
    1
  • 氢受体数:
    5

SDS

SDS:f743238c8600809ddd9629e84afaf462
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    申请人:Heald Robert
    公开号:US20120202785A1
    公开(公告)日:2012-08-09
    Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    化学式I类化合物,包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐,对抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病,如炎症、免疫性疾病和癌症,具有用途。公开了利用化合物I类进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病,或相关的病理状况的方法。
  • <i>N</i>-Nitroso and<i>C</i>-Nitro Derivatives from Di-(2-pyridyl)amine and Butyl Nitrite
    作者:Angelo G. Giumanini、Marco Poiana、Giancarlo Verardo、Paolo Strazzolini、Marilena Tolazzi、Giovanni Cerioni
    DOI:10.1246/bcsj.67.1641
    日期:1994.6
    The reaction between di-(2-pyridyl)amine and butyl nitrite produced N-nitrosodi-(2-pyridyl)amine, (5-nitro-2-pyridyl)-2-pyridylamine and (3-nitro-2-pyridyl)-2-pyridylamine of which the likely conformations are evinced from spectral data. Structural elucidation of N-nitrosodi-(2-pyridyl)amine in the solid state by X-ray diffraction excluded any substantial contribution of the rings to resonance structures.
    二-(2-吡啶基)胺与亚硝酸丁酯反应生成N-亚硝基二-(2-吡啶基)胺、(5-硝基-2-吡啶基)-2-吡啶胺和(3-硝基-2-吡啶基)- 2-吡啶胺,其可能的构象由光谱数据表明。通过 X 射线衍射对固态 N-亚硝基二-(2-吡啶基)胺的结构阐明排除了环对共振结构的任何实质性贡献。
  • 1,3-Dihydro-imidazo-(4,5-b)-pyridin-2-ones
    申请人:Roussel Uclaf
    公开号:US04195088A1
    公开(公告)日:1980-03-25
    Novel 1,3-dihydro-imidazo-(4,5-b)-pyridin-2-ones of the formula ##STR1## wherein R is alkyl of 1 to 3 carbon atoms and R' is pyridyl and Y is selected from the group consisting of hydrogen and chlorine and their non-toxic, pharmaceutically acceptable acid addition salts having gastric anti-secretic and anti-ulcerogenic and anorexigenic activity and a novel process and novel intermediates for their preparation.
    该文本描述一种新型化合物,其名称为1,3-双氢-咪唑-(4,5-b)-吡啶-2-酮,其化学式为##STR1## 其中R代表1至3个碳原子的烷基,R'代表吡啶基,Y可以是氢或,以及其无毒、药学上可接受的酸盐衍生物。该化合物具有胃抑酸、抗溃疡和食欲抑制活性。此外,该文本还介绍了一种制备该化合物的新方法和新中间体。
  • Heterobicyclic derivatives
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:US20020107251A1
    公开(公告)日:2002-08-08
    Heterobicyclic derivatives of the formula: 1 wherein R 1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R 2 is aryl which may have suitable substituent(s) or heterocyclic group, and R 3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.
    公式为1的杂环双环衍生物,其中:R1是苯基,可以具有适当的取代基;芳基(较低)烷基,可以具有适当的取代基;卤代(较低)烷基;保护的羧基(较低)烷基;酰基(较低)烷基;杂环基或者可以具有适当的取代基的杂环(较低)烷基;R2是苯基,可以具有适当的取代基或者杂环基;R3是氢、较低烷氧基或者芳基醚。它们的药物可接受盐是有用的。
  • Heterocyclic compounds and methods of use
    申请人:Heald Robert
    公开号:US08653089B2
    公开(公告)日:2014-02-18
    Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    包括立体异构体、几何异构体、互变异构体、代谢物和药学上可接受的盐在内的公式I化合物,可用于抑制PI3K的δ异构体,并用于治疗由脂质激酶介导的疾病,如炎症、免疫性疾病和癌症。本文揭示了使用公式I化合物进行哺乳动物细胞内、原位和体内诊断、预防或治疗此类疾病或相关病理状态的方法。
查看更多